# Corinne Faivre‐Finn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/corinne-faivre-finn/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,257 |
| Field | Lung Cancer Diagnosis and Treatment |
| h-index | 76 |
| i10-index | 254 |
| Last Known Institution | University of Manchester |
| OpenAlex ID | https://openalex.org/A5007868555 |
| ORCID iD | https://orcid.org/0000-0001-5617-9781 |
| Works | 908 |

## Researcher papers

- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for-2/)
- [Small-cell lung cancer](https://scholariq.org/papers/small-cell-lung-cancer/)
- [Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI](https://scholariq.org/papers/reporting-guideline-for-the-early-stage-clinical-evaluation-of-decision-support/)
- [Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆](https://scholariq.org/papers/small-cell-lung-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment/)
- [2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up](https://scholariq.org/papers/2nd-esmo-consensus-conference-on-lung-cancer-early-stage-non-small-cell-lung/)
- [Non-small-cell lung cancer](https://scholariq.org/papers/non-small-cell-lung-cancer-2/)
- [Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial](https://scholariq.org/papers/four-year-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-an/)
- [Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC](https://scholariq.org/papers/three-year-overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii/)
- [Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus](https://scholariq.org/papers/managing-cancer-patients-during-the-covid-19-pandemic-an-esmo-multidisciplinary/)
- [Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer](https://scholariq.org/papers/second-esmo-consensus-conference-on-lung-cancer-pathology-and-molecular/)

## Researcher topics

- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)

## Researcher university

- [University of Manchester](https://scholariq.org/institutions/university-of-manchester/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.